Healthcare utilization and costs associated with first-line treatment with obinutuzumab- and rituximab-based regimens for follicular lymphoma. This is an ASCO Meeting Abstract from the 2021 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results